Aarti Pharmalabs · NSE: AARTIPHARM · BSE: 543748
Q3 FY24 results · Oct–Dec 2023
Aarti Pharmalabs reported revenue from operations of ₹448.69 crore and net profit of ₹52.76 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 448.69 | — | — | 439.80 | +2.0% |
| Other income | 1.39 | — | — | 0.98 | +42.2% |
| Total income | 450.08 | — | — | 440.78 | +2.1% |
| Profit before tax | 73.82 | — | — | 66.95 | +10.3% |
| Net profit for the period | 52.76 | — | — | 51.80 | +1.9% |
| EPS, basic (₹) | 5.82 | — | — | 5.72 | +1.7% |
| Net margin (%) | 11.8 | — | 11.8 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 373.03 | — | — | 356.14 | +4.7% |
| Other income | 0.20 | — | — | 0.00 | — |
| Total income | 373.23 | — | — | 356.14 | +4.8% |
| Profit before tax | 67.44 | — | — | 53.66 | +25.7% |
| Net profit for the period | 48.19 | — | — | 41.18 | +17.0% |
| EPS, basic (₹) | 5.32 | — | — | 4.61 | +15.4% |
| Net margin (%) | 12.9 | — | 11.6 |
Consolidated
- Filed with BSE
- 08 Feb 2024, 11:12 IST
- Board meeting
- 07 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Feb 2024, 11:12 IST
- Board meeting
- 07 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Audited
- Source
- XBRL filing on BSE